Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Apr 16, 2015; 3(4): 330-337
Published online Apr 16, 2015. doi: 10.12998/wjcc.v3.i4.330
Published online Apr 16, 2015. doi: 10.12998/wjcc.v3.i4.330
Bleeding and clotting in hereditary hemorrhagic telangiectasia
Christopher Dittus, Section of Hematology and Medical Oncology, Boston University Medical Center, Boston, MA 02118, United States
Michael Streiff, Department of Medicine, Johns Hopkins University, Baltimore, MD 21287, United States
Jack Ansell, Hofstra North Shore-LIJ School of Medicine, Hofstra University, Hempstead, NY 11549, United States
Author contributions: All authors contributed to this manuscript.
Conflict-of-interest: Dr. Dittus has no conflicts to report. Dr. Streiff has received research funding from Sanofi-Aventis, Bristol Myers Squibb and Portola, honoraria for CME lectures from Sanofi-Aventis and Ortho-McNeil, consulted for Sanofi-Aventis, Eisai, Daiichi-Sankyo, Boehringer-Ingelheim and Janssen HealthCare and has given expert witness testimony in various medical malpractice cases. Dr. Ansell serves as a consultant for Bristol Myers Squibb, Janssen, Boehringer Ingelheim, Pfizer, and Daiichi Sankyo Pharmaceuticals.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Christopher Dittus, DO, MPH, Section of Hematology and Medical Oncology, Boston University Medical Center, FGH Building, First Floor, 820 Harrison Avenue, Boston, MA 02118, United States. cedittus@gmail.com
Telephone: +1-917-7540887 Fax: +1-617-4141831
Received: October 23, 2014
Peer-review started: October 24, 2014
First decision: November 27, 2014
Revised: January 7, 2015
Accepted: January 18, 2015
Article in press: January 20, 2015
Published online: April 16, 2015
Processing time: 172 Days and 7.5 Hours
Peer-review started: October 24, 2014
First decision: November 27, 2014
Revised: January 7, 2015
Accepted: January 18, 2015
Article in press: January 20, 2015
Published online: April 16, 2015
Processing time: 172 Days and 7.5 Hours
Core Tip
Core tip: This article reviews an inherited disorder, hereditary hemorrhagic telangiectasia, in the context of a complicated clinical case. It highlights the problem of balancing the risks of bleeding and thrombosis, and raises the question of whether the new oral anticoagulants might provide safer therapy in such patients who need antithrombotic therapy.